Literature DB >> 16837469

Differential mapping of the amino acids mediating agonist and antagonist coordination with the human thromboxane A2 receptor protein.

Fadi T Khasawneh1, Jin-Sheng Huang, Joseph W Turek, Guy C Le Breton.   

Abstract

Despite the well documented involvement of thromboxane A(2) receptor (TPR) signaling in the pathogenesis of thrombotic diseases, there are currently no rationally designed antagonists available for clinical use. To a large extent, this derives from a lack of knowledge regarding the topography of the TPR ligand binding pocket. On this basis, the purpose of the current study was to identify the specific amino acid residues in the TPR protein that regulate ligand coordination and binding. The sites selected for mutation reside within or in close proximity to a region we previously defined as a TPR ligand binding region (i.e. the C terminus of the second extracellular loop and the leading edge of the fifth transmembrane domain). Mutation of these residues caused varying effects on the TPR-ligand coordination process. Specifically, the D193A, D193Q, and D193R mutants lost SQ29,548 (antagonist) binding and exhibited a dramatically reduced calcium response, which could not be restored by elevated U46619 (agonist) doses. The F184Y mutant lost SQ29,548 binding and exhibited a reduced calcium response (which could be restored by elevated U46619); and the T186A and S191T mutants lost SQ29,548 binding and retained a normal U46619-induced calcium response. Furthermore, these last three mutants also revealed a divergence in the binding of two structurally different antagonists, SQ29,548 and BM13.505. Two separate mutants that exhibited SQ29,548 binding yielded either a normal (F196Y) or reduced (S201T) U46619 response. Finally, mutation of other residues directly adjacent to those described above (e.g. E190A and F200A) produced no detectable effects on either SQ29,548 binding or the U46619-induced response. In summary, these results identify key amino acids (in particular Asp(193)) involved in TPR ligand coordination. These findings also demonstrate that TPR-specific ligands interact with different residues in the ligand-binding pocket.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16837469     DOI: 10.1074/jbc.M507469200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  2-Aminoethyl methylphosphonate, a potent and rapidly acting antagonist of GABA(A)-ρ1 receptors.

Authors:  An Xie; Jun Yan; Lan Yue; Feng Feng; Fozia Mir; Heba Abdel-Halim; Mary Chebib; Guy C Le Breton; Robert F Standaert; Haohua Qian; David R Pepperberg
Journal:  Mol Pharmacol       Date:  2011-08-02       Impact factor: 4.436

2.  Repurposing an old drug for a new use: glybenclamide exerts antiplatelet activity by interacting with the thromboxane A(2) receptor.

Authors:  Harold J Ting; Wallace J Murray; Fadi T Khasawneh
Journal:  Acta Pharmacol Sin       Date:  2010-02       Impact factor: 6.150

3.  Distinguishing the interactions in the fructose 1,6-bisphosphate binding site of human liver pyruvate kinase that contribute to allostery.

Authors:  Arjun Ishwar; Qingling Tang; Aron W Fenton
Journal:  Biochemistry       Date:  2015-02-12       Impact factor: 3.162

4.  Distinct second extracellular loop structures of the brain cannabinoid CB(1) receptor: implication in ligand binding and receptor function.

Authors:  Joong-Youn Shim; James Rudd; Tomas T Ding
Journal:  Proteins       Date:  2011-02

Review 5.  Understanding functional residues of the cannabinoid CB1.

Authors:  Joong-Youn Shim
Journal:  Curr Top Med Chem       Date:  2010       Impact factor: 3.295

6.  Subunit-specific polyclonal antibody targeting human ρ1 GABA(C) receptor.

Authors:  Hélène A Gussin; Fadi T Khasawneh; An Xie; Feng Feng; Adnan Memic; Haohua Qian; Guy C Le Breton; David R Pepperberg
Journal:  Exp Eye Res       Date:  2011-04-23       Impact factor: 3.467

7.  Characterization of isoprostane signaling: evidence for a unique coordination profile of 8-iso-PGF(2alpha) with the thromboxane A(2) receptor, and activation of a separate cAMP-dependent inhibitory pathway in human platelets.

Authors:  Fadi T Khasawneh; Jin-Sheng Huang; Fozia Mir; Subhashini Srinivasan; Chinnaswamy Tiruppathi; Guy C Le Breton
Journal:  Biochem Pharmacol       Date:  2008-03-30       Impact factor: 5.858

8.  A novel thromboxane A2 receptor D304N variant that abrogates ligand binding in a patient with a bleeding diathesis.

Authors:  Andrew D Mumford; Ban B Dawood; Martina E Daly; Sherina L Murden; Michael D Williams; Majd B Protty; Jennifer C Spalton; Mark Wheatley; Stuart J Mundell; Steve P Watson
Journal:  Blood       Date:  2009-10-14       Impact factor: 22.113

Review 9.  Molecular mechanisms of target recognition by lipid GPCRs: relevance for cancer.

Authors:  M T M van Jaarsveld; J M Houthuijzen; E E Voest
Journal:  Oncogene       Date:  2015-12-07       Impact factor: 9.867

Review 10.  Pathophysiology of isoprostanes in the cardiovascular system: implications of isoprostane-mediated thromboxane A2 receptor activation.

Authors:  Jochen Bauer; Anne Ripperger; Stefan Frantz; Süleyman Ergün; Edzard Schwedhelm; Ralf A Benndorf
Journal:  Br J Pharmacol       Date:  2014-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.